China Blood Product Industry Report, 2006-2007
  • Apr.2007
  • Hard Copy
  • USD $399 $200
  • Pages:21
  • Single User License
    (PDF Unprintable)       
  • USD $399 $200
  • Code:
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $798 $399
  • Hard Copy + Single User License
  • USD $599 $300

Blood product belongs to biological products and is a biological active preparation which collects healthy blood as the raw material and then is made through biological process or separation and purification technologies. Blood products are irreplaceable in the application of medical emergency and prevention & treatment to some specific diseases.  

China blood product industry is about to see a fast and steady growth: due to the increasing population, high incidence rate of malignant disease and growing national economy, blood product market demands are expected to remain growing at 15% annually; China didn’t approve to found new blood product enterprises since 2001, which together with imports limit creates a relatively stable competition environment; after plasma collection stations got restructured, blood product industry chain has become more flexible, which is favor to a long-term development; and industrial supervision will be increasingly strict. 

Since the state started regulating plasma collection stations in 2004, plasma volume collected has been sliding, to 3,000 tons in 2005 and 2006. As plasma collection stations finished the restructuring, the plasma volume collected has been gradually increasing but plasma supply still falls short presently. The supply and demand are expected to come to a balance by 2008. 

Trend of Plasma Volume Collected in China, 2001-2008

When the restructuring is over, plasma volume collected is ready to still play an important role for the blood product enterprises to get developed but more important is the ability to manage plasma source. Plasma source management is mainly focused on plasma source scale management and plasma source quality control. Plasma source quality is measured by collected volume of featured plasma, plasma donors’ management and guarantee to plasma security.
Plasma price keeps growing steadily even after plasma collection stations are restructured, which is because, on the one hand, plasma supply is gradually coming back but still in short; on the other hand, plasma price is quite transparent and even if the cost is added under the counter, it can be seen on the final price. 

China still can’t meet the demands for plasma during 2006-2008 periods; as a result, human serum albumin price will keep high during 2007-2008 periods.

Leading enterprises have fostered strong competitive advantages from upstream—quantity, quality and management of plasma collection stations to downstream products’ R & D, production and distribution. There will form 2-3 nationwide leader and 5-6 regional leaders in China blood product industry in the future while those small weak enterprises will be phased out.

1 Overview of development environments of China blood product industry
1.1 Restructuring of plasma collection stations
1.2 Profitability environments
1.3 Industrial supervision gets increasingly strict

2 China blood product market
2.1 Plasma volume collected
2.2 Plasma price
2.3 Human serum albumin price
2.4 Competition pattern

3 Key blood product enterprises of China 
3.1 Hualan Biological Engineering Inc.
3.2 Shanghai RAAS Blood Products Co., Ltd
3.3 Rongsheng Pharmaceuticals
3.4 Shanghai Institute of Biological Products
Market structure of raw plasma volume used in China, 2005
Product lines of domestic key blood product enterprises
Blood product industry chain before the restructuring of plasma collection stations
Blood product industry chain after the restructuring of plasma collection stations
Trend of plasma volume collected in China, 2001-2008
Plasma price trend of China, 1994-2008
Price trend of human serum albumin in China, 1994-2006
Oligarch monopoly pattern of China blood product industry

Global and China DNA Sequencing Industry Research Report, 2014-2017

DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a...

Global and China Stem Cell Industry Report, 2014-2017

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatmen...

China Human Vaccine Industry Report, 2014-2017

Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlie...

China Blood Product Industry Report, 2014-2017

Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption t...

China Animal Vaccine Industry Report, 2013-2016

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. Europe and the United States and other developed countries are the main ...

China Contract Research Organization (CRO) Industry Report, 2013-2016

China CRO industry has developed rapidly in recent years, registering a CAGR of 27.2% during 2007-2013, of which the market size reached RMB 36 billion in 2013, occupying 10% of global market share. ...

Global and China Biodegradable Plastics Industry Report, 2013-2016

Global biodegradable plastic production and demand have grown rapidly in recent years, and the capacity reached 1-1.5 million t/a in 2012-2013. Among dozens of biodegradable plastic varieties develope...

Global and China Industrial Enzyme Industry Report, 2014-2016

In 2007-2013, the global industrial enzyme market size grew at the CAGR of 5.7%, reaching USD4.04 billion in 2013, 1.4 times that in 2007. The global industrial enzyme market is monopolized by a small...

China Heparin Industry Report, 2013-2015

Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradual...

China Lactic Acid and Derivative Industry Report, 2013

China’s lactic acid capacity and output continued to grow at the respective CAGR of 22.7% and 28.7% in 2007-2011. But limited by market demand, the annual output of most vendors was below their design...

China Human Vaccine Industry Report, 2012-2015

In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the...

China Blood Product Industry Report, 2012-2015

Plasma is a key raw material of the blood product industry. In August 2011, China shut down 16 plasma stations in Guizhou, resulting in a decrease of 15% in the plasma volume of the year. However, due...

China Animal Vaccine Industry Report, 2012-2015

In view of the frequent occurrence of animal epidemic diseases over the years, the Chinese government has increased investment in epidemic prevention and implemented compulsory immunization system. Be...

Global and China Monoclonal Antibody Industry Report, 2013

In recent years, the monoclonal antibody market around the globe has witnessed substantial growth, and the CAGR of market scale during 1997-2011 has reached 44% approximately. It is predicted that the...

China Insulin Industry Report, 2012-2015

China is a country with the largest number of diabetics. In 2011, the market scale of diabetes medicine in China approximated RMB13.8 billion, of which, insulin medicines mainly comprising recombinant...

China Heparin Industry Report, 2012-2014

China, abundant in heparin raw materials, has become one of the world’s largest heparin API producers and exporters, owning to the quality of heparin API having won international recognition gradually...

Global and China Industrial Enzyme Industry Report, 2012-2014

Industrial enzyme which refers to the enzyme preparation used for industrial purposes can be applied to detergent, animal feed, bread, brewing (beer, wine, etc.), papermaking, textile, bio-ethanol and...

China Blood Products Industry Report, 2011-2012

Blood plasma serves as key raw material in blood product industry. In August 2011, the shut-down of 16 plasma collection stations in Guizhou province, China resulted in a YoY decline of 15% in plasma ...

2005-2014 All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号